ID: ALA3735506

Max Phase: Preclinical

Molecular Formula: C23H26F2N4O2

Molecular Weight: 428.48

Molecule Type: Small molecule

Representations

Canonical SMILES:  COCCN1CCC(CNC(=O)c2n[nH]c3ccc(-c4cccc(F)c4F)cc23)CC1

Standard InChI:  InChI=1S/C23H26F2N4O2/c1-31-12-11-29-9-7-15(8-10-29)14-26-23(30)22-18-13-16(5-6-20(18)27-28-22)17-3-2-4-19(24)21(17)25/h2-6,13,15H,7-12,14H2,1H3,(H,26,30)(H,27,28)

Standard InChI Key:  QCLXNOBXQUWUEW-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 428.48

Molecular Weight (Monoisotopic): 428.2024

AlogP: 3.60

#Rotatable Bonds: 7

Polar Surface Area: 70.25

Molecular Species: BASE

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 9.78

CX Basic pKa: 8.91

CX LogP: 2.80

CX LogD: 1.57

Aromatic Rings: 3

Heavy Atoms: 31

QED Weighted: 0.60

Np Likeness Score: -1.65

References

1. Furlotti G, Alisi MA, Cazzolla N, Dragone P, Durando L, Magarò G, Mancini F, Mangano G, Ombrato R, Vitiello M, Armirotti A, Capurro V, Lanfranco M, Ottonello G, Summa M, Reggiani A..  (2015)  Hit Optimization of 5-Substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: Potent Glycogen Synthase Kinase-3 (GSK-3) Inhibitors with in Vivo Activity in Model of Mood Disorders.,  58  (22): [PMID:26486317] [10.1021/acs.jmedchem.5b01208]

2. Prati F, Buonfiglio R, Furlotti G, Cavarischia C, Mangano G, Picollo R, Oggianu L, di Matteo A, Olivieri S, Bovi G, Porceddu PF, Reggiani A, Garrone B, Di Giorgio FP, Ombrato R..  (2020)  Optimization of Indazole-Based GSK-3 Inhibitors with Mitigated hERG Issue and In Vivo Activity in a Mood Disorder Model.,  11  (5): [PMID:32435391] [10.1021/acsmedchemlett.9b00633]

Source

Source(1):

• Scientific Literature